Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 14, 2025Expert Review of Clinical Immunology

Immune pathways, current and potential therapies in Mycosis Fungoides and sezary syndrome

View Full Paper
Ask AI
Bookmark
Share

Authors

FBFriyana BhabhaCWCarrie Van Der WeydenJCJoshua Casan

Discussion

Loading...

Member takes

Overview

This review examines immunotherapies and targeted therapies for mycosis fungoides and Sézary syndrome, highlighting current clinical outcomes and potential innovations.

Key Points

  • Mycosis fungoides is the most common form of cutaneous T cell lymphoma, while Sézary syndrome represents a more aggressive subtype.
  • Large cell transformation is rare in mycosis fungoides and associated with a poor prognosis.
  • Accelerating understanding of the tumor microenvironment is critical to developing targeted therapies for patients.
  • Emerging immunotherapies and biologic agents promise improved clinical outcomes for advanced cutaneous T cell lymphomas.

Cite This Study

Bhabha et al. (2025) studied this question.

synapsesocial.com/papers/689a02b6e6551bb0af8cc2b1https://doi.org/10.1080/1744666x.2025.2533367
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Th2 Cytokine mRNA Expression in Skin in Cutaneous T-Cell Lymphoma1994 · 267 citations
  2. 2Advances in the treatment of mycoses fungoides and Sézary syndrome: a narrative update in skin-directed therapies and immune-based treatments2023 · 22 citations
  3. 3Immune Check Point Inhibitors in Primary Cutaneous T-Cell Lymphomas: Biologic Rationale, Clinical Results and Future Perspectives2021 · 34 citations
  4. 4British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous lymphomas 20182018 · 164 citations
  5. 5Cutaneous T‐cell lymphoma following dupilumab use: a systematic review2022 · 65 citations